Krug Associates’ Post

Interesting to know the top drugs losing exclusivity in the biggest global pharma market. Their combined accumulated sales in the US alone were $ 4.5 billion in 2023. There's always uncertainty stemming from legal and regulatory developments, which can affect generic and biosimilar launch timing. This presents a huge opportunity for generic and biosimilar companies to take market shares and launch before their competitors globally if they planned it well in advance. For innovative pharma companies, it’s a reminder about the need for new launches to replace revenue lost to the patent cliff. #innovation #pharmaceuticals  #technology #medtech

Navigating the realm of pharmaceutical exclusivity, this report delves into the latest developments featuring Bristol Myers Squibb, Biogen, Novo Nordisk, Astellas, and Novartis, showcasing their blockbuster medications and storied histories. Additionally, it sheds light on companies such as PTC Therapeutics, Organon, Supernus, CSL, and Bausch + Lomb, who are poised to encounter significant potential losses in exclusivity throughout 2024. Embark on a journey through the evolving landscape of pharmaceuticals, tracing the path from exclusivity to new horizons. https://lnkd.in/dhvbzQnp Making changes? Let's have a conversation. At #SECORA our methodologies are proven in success to accelerate operational distinction in highly regulated industries. We have methods that address: Process Design & Optimisation, Lean & CIP Implementation, Project & Launch Management, Organization Development, Restructuring and Sustainability, and Supply Chain & Development. Visit www.secora.de for more info.

The top 10 drugs losing US exclusivity in 2024 > Fierce Pharma has assembled the list of the top drugs expected to face that fate in 2024. For inclusion in this report, we consider the drugs most likely to face new generic or biosimilar competition this calendar year, ranked by U.S. sales from last year.

🚀 Pharma Execs Alert! 🚀 Time's relentless march means one thing for pharma execs: the urgency of new launches to offset revenue lost to the patent cliff. Consider Humira, a global sales titan peaking at over $21 billion. Despite its success, it faced biosimilars in 2023, leading to a sharp decline. At Fierce Pharma, we've compiled the top drugs set to face this fate in 2024. From Bristol Myers Squibb to Novartis, these blockbusters are on the radar. Navigating legal and regulatory uncertainties, our report uses a mix of company filings and outside sources for reliability. Get ahead with insights from Corporate Pharmacy Services, Biospace, and OptumRx. See the full report👉 https://ow.ly/CPxf50QQBiR Stay updated on all our events by following Fierce Life Sciences Events #FierceBiotech #FierceLifeSciencesEvents #FiercePharma #WeAreFierce

The 340B Drug Pricing Program’s rapid growth has created a complex web of financial and legislative challenges for pharma companies. Ricky Yuen and Nick Porter check in on how pharma and states are responding to the program as it changes. https://bit.ly/3KG2LmT #healthcare #pharma #drugpricing

Elevate your team's performance with @ReutersEventsPharma. Discover and bridge capability gaps to drive success. Visit our team of experts from across Inizio on booth 314-316 this week. #REpharmaUSA #Inizio #Pharma #Commercialization #CustomerEngagement #Inizio #ReimagineHealth #ConnectedCapabilities

The 340B Drug Pricing Program’s rapid growth has created a complex web of financial and legislative challenges for pharma companies. My colleagues Nick Porter Neelabh Saxena Harshil Gagnani Shreya Bhatia dive into pharma’s and states’ responses to the program’s evolution and the effectiveness of these strategies. Since we drafted this whitepaper, several more manufacturers and states have evolved their policies, showing just how dynamic this space really is! Download the white paper to find out how pharma can adapt. #healthcare #pharma #340B #drugpricing #publicpolicy https://lnkd.in/eXczZneB

Stand Up Against Big Pharma's Greed: Join Our Digital Day of Action! 📅 Date: June 27th 💻 Where: P4AD Facebook Live 📢 Event: Panel Discussion on Defending Medicare Negotiation and Big Pharma's Lawsuits to Block the Critical Program 🔗 RSVP: https://lnkd.in/e7mYPPrP Big Pharma has filed 9 lawsuits to block Medicare from negotiating lower drug prices. Their greed has forced many patients to ration their medications or skip treatments because of the outrageous costs of their medications. Join us on June 27th for a virtual panel discussion where experts will highlight the critical need for Medicare negotiation. We aim to gather 250,000 signatures demanding that pharmaceutical CEOs #DropTheSuits and prioritize patients over profits. #FightPharma

Stand Up Against Big Pharma's Greed: Join Our Digital Day of Action! 📅 Date: June 27th 💻 Where: P4AD Facebook Live 📢 Event: Panel Discussion on Defending Medicare Negotiation and Big Pharma's Lawsuits to Block the Critical Program 🔗 RSVP: https://lnkd.in/e7mYPPrP Big Pharma has filed 9 lawsuits to block Medicare from negotiating lower drug prices. Their greed has forced many patients to ration their medications or skip treatments because of the outrageous costs of their medications. Join us on June 27th for a virtual panel discussion where experts will highlight the critical need for Medicare negotiation. We aim to gather 250,000 signatures demanding that pharmaceutical CEOs #DropTheSuits and prioritize patients over profits. #FightPharma

The 340B Drug Pricing Program has grown significantly in recent years. States have responded by passing additional legislation, creating a complex policy landscape that’s challenging for both manufacturers and providers. My colleagues explore pharma’s and states’ policy responses, analyze how successful these responses have been and offer recommendations for how pharma can adapt in a dynamic environment.  #healthcare #pharma #340B #drugpricing #publicpolicy https://lnkd.in/eJwm-NrN